Amiko: Amiko wins CE Mark to integrate drug sensor tech into inhalers

Amiko Digital Health said today that it received CE Mark clearance to integrate its Respiro medication sensor tech with Teva Pharmaceuticals' (NYSE:TEVA) Spiromax inhaler, Chiesi's Nexthaler device and GlaxoSmithKline's (NYSE:GSK) Ellipta inhaler. The company's Respiro platform is designed to help doctors monitor, in real-time, when and how well patients are using their medications. Get the full story at our [...]The post Amiko wins CE Mark to integrate drug sensor tech into inhalers appeared first on MassDevice.